追踪2024年成人流感住院患者的临床严重程度:来自波兰FluTer登记处的数据
该回顾性研究分析波兰13个感染病单元FluTer登记处2024年298例流感住院患者,住院数较2023年增加326%,但全国监测报告流感发病率三年最低。2024年9–12月院内死亡率6.1%,12月达7.2%,高于2022年1.7%和2023年5.1%;2024年所有死亡均发生在未接种疫苗者中。
要点
- 2024年298例流感住院,较2023年增加326%,而全国监测报告流感发病率三年最低。
- 2024年9–12月院内死亡率6.1%,12月7.2%,高于2022年1.7%和2023年5.1%。
- 2024年所有死亡均发生在未接种疫苗者中;95.2%患者接受奥司他韦,超60%因细菌合并感染使用抗生素。
核心结论
- 住院和死亡上升可能源于人群易感性和大流行后效应,而非病毒毒力增强。
- 研究强调需提高疫苗接种覆盖率、加强监测和及时获得抗病毒药物。
- 通过更好的流感预防减少抗生素过度使用对应对抗生素耐药至关重要。
- 继续通过FluTer登记处监测对优化流感管理和防范至关重要。
研究设计与样本
- 回顾性研究,数据来自波兰13个参与FluTer登记处的感染病单元。
- 共记录2024年298例流感相关住院,并与全国监测数据比较。
- 分析患者特征、症状、实验室结果和临床严重程度,比较2023/2024流行季1–8月与2024/2025流行季9–12月,包括性别差异。
主要发现
- 2024年298例流感相关住院,较2023年增加326%,而全国监测报告流感发病率三年最低。
- 95.1%病例为甲型流感;37.2%住院和57.1%院内死亡发生在2024年12月。
- 住院患者以老年人、未接种疫苗者、肥胖或有合并症者为主。
- 2024年初与年末患者特征无显著差异,仅后期外周血管疾病和哮喘患病率更高。
- 2024年9–12月院内死亡率6.1%,12月达7.2%,高于2022年1.7%和2023年5.1%;2024年所有死亡均发生在未接种疫苗者中。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In late 2024, infectious disease specialists in Poland became alarmed about increased influenza-related hospitalizations, prompting concerns about disease severity shifts and underlying causes. Therefore, this retrospective study aimed to analyze the demographic and clinical characteristics of hospitalized influenza patients in 2024. Data were collected from thirteen infectious disease units participating in the FluTer registry. Hospitalization trends were compared with national surveillance data. Patient profiles, symptoms, laboratory results, and clinical severity were analyzed across early (2023/2024 epidemic season; January-August) and late 2024 (2024/2025 season; September-December), including sex-based differences. A total of 298 influenza-related hospitalizations were recorded in 2024, representing a 326 % increase from 2023, despite national surveillance reporting the lowest influenza incidence in three years. The majority (95.1 %) of cases were due to type A influenza, with 37.2 % of hospitalizations and 57.1 % of in-hospital deaths occurring in December 2024. Hospitalized patients were predominantly elderly, unvaccinated, obese, or had comorbidities. There were no significant differences in patient characteristics between the beginning and end of 2024, apart from a higher prevalence of peripheral vascular disease and asthma in later months. In-hospital mortality between September and December 2024 reached 6.1 %, peaking at 7.2 % in December. This was higher than the rates recorded in 2022 (1.7 %) and 2023 (5.1 %). Notably, all deaths in 2024 occurred among unvaccinated individuals. Nearly all patients (95.2 %) received oseltamivir, and over 60 % required antibiotics due to bacterial coinfections. The rise in hospitalizations and mortality likely resulted from population vulnerability and post-pandemic effects rather than increased viral severity. Findings emphasize the need for improved vaccination coverage, enhanced surveillance, and timely antiviral access. Reducing antibiotic overuse through better influenza prevention is crucial for combating antibiotic resistance. Continued monitoring through the FluTer registry is essential for optimizing influenza management and preparedness.
引用
- Rzymski P, Pleśniak R, Piekarska A, et al. Tracking clinical severity of influenza in adult hospitalized patients in 2024: Data from the FluTer registry in Poland. Vaccine. 2025. PMID: 40602348. doi:10.1016/j.vaccine.2025.127443
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。